Vaxart: Positive Top-line Phase II Data for COVID-19 Pill Vaccine

 Study met primary safety and secondary immunogenicity endpoints —

— Boosted serum neutralizing antibodies in both naive and previously mRNA vaccinated subjects —

— Elicited cross-reactive mucosal responses in approximately 50% of subjects —

— Company to host conference call at 8:30 a.m. ET today —

The Vaxart senior management team will host a conference call today, beginning at 8:30 a.m. ET.

The conference call can be accessed using the following information:
Webcast: Click here
Date: Thursday, September 1, 2022 – 8:30 a.m. ET
Domestic: 877-407-0832
International: 201-689-8433
Conference ID: 13732510

Investors may submit written questions in advance of the conference call to ir@vaxart.com. A replay of the webcast will be available on the Company’s website at www.vaxart.com following the conclusion of the event.

https://finance.yahoo.com/news/vaxart-announces-positive-top-line-103000580.html